# StimLabs Theracor Receives FDA 510(k) Clearance as First Human Umbilical Cord-Derived Wound Sheet Device

> fda · REPORTED · 2026-01-15

StimLabs received FDA 510(k) clearance for Theracor, making it the first human umbilical cord-derived wound sheet device cleared for managing acute and chronic wounds including diabetic ulcers, venous ulcers, pressure ulcers, and surgical wounds. The clearance positions Theracor as a novel regenerative entry in the advanced wound care market.

About StimLabs: StimLabs is a regenerative medicine company that develops biologically derived wound care products sourced from human birth tissue, targeting clinicians treating patients with complex acute and chronic wounds.

- Company: StimLabs
- Sector: medical devices
- Primary source: https://www.openpr.com/news/4539050/chronic-wounds-pipeline-2026-fda-updates-therapy

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.